摘要
目的探讨氟伐他汀对ACS患者血清IL-18、TNF-α和hs-CRP水平的影响及其对心血管事件发生率的影响。方法随机选取本院心内科2012年8月~2015年8月收治的68例ACS患者,依据随机数字表法分这些患者为氟伐他汀治疗组(n=34)和常规治疗组(n=34)。另选取同期来本院进行体检的34名健康人员作为对照组,给予常规治疗组患者常规治疗,给予氟伐他汀治疗组患者常规治疗基础上氟伐他汀治疗。结果氟伐他汀治疗组患者的血清IL-18、TNF-α和hs-CRP水平均显著低于常规治疗组(P<0.05),心绞痛、心肌梗死、心力衰竭、死亡等心血管事件发生率5.9%(2/34)、2.9%(1/34)、2.9%(1/34)、2.9%(1/34)均显著低于常规治疗组20.6%(7/34)、17.6%(6/34)、11.8%(4/34)、8.8%(3/34)(P<0.05),两组患者的血清IL-18、TNF-α和hs-CRP水平均显著高于对照组(P<0.05)。结论氟伐他汀能够有效降低ACS患者血清IL-18、TNF-α和hs-CRP水平及心血管事件发生率,值得在临床推广使用。
Objective To investigate the influences of fluvastatin in serum IL-18,TNF-α and hs-CRP levels and cardiovascular events of patients with ACS.Methods 68 cases of ACS patients who were treated in Cardiology of our hospital during August 2012 to August 2015 were randomly selected,these patients were divided into fluvastatin treatment group(n=34) and conventional therapy group(n=34) two groups according to a random number table.another 34 cases of healthy people to our hospital for medical examination in the same year were selected as control group,The conventional therapy group were given conventional treatment,while the fluvastatin treatment group were given fluvastatin therapy based on conventional therapy.Results The serum IL-18,TNF-αand hs-CRP levels of the fluvastatin treatment group were significantly lower(P<0.05),the angina pectoris,myocardial infarction,heart failure and death rates of cardiovascular events 5.9%(2/34),2.9%(1/34),2.9%(1/34),2.9%(1/34) were significantly lower than the conventional therapy group 20.6%(7/34),17.6%(6/34),11.8%(4/34),8.8%(3/34)(P<0.05),the serum IL-18,TNF-αand hsCRP levels of the two groups were significantly higher than the control group(P<0.05).Conclusion Fluvastatin can effectively reduce the serum IL-18,TNF-αand hs-CRP levels and cardiovascular events of patients with ACS,so is worthy of promotion.
出处
《当代医学》
2018年第2期36-39,共4页
Contemporary Medicine
